Abstract
Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Current Stem Cell Research & Therapy
Title:A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future
Volume: 13 Issue: 8
Author(s): Amirhosein Maali, Amir Atashi, Sasan Ghaffari, Reza Kouchaki, Fereshteh Abdolmaleki and Mehdi Azad*
Affiliation:
- Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin,Iran
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Abstract: Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.
Export Options
About this article
Cite this article as:
Maali Amirhosein , Atashi Amir , Ghaffari Sasan , Kouchaki Reza , Abdolmaleki Fereshteh and Azad Mehdi *, A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future, Current Stem Cell Research & Therapy 2018; 13 (8) . https://dx.doi.org/10.2174/1574888X13666180731155038
DOI https://dx.doi.org/10.2174/1574888X13666180731155038 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance
Current Pharmaceutical Design The Central Role of Leukotriene B4 in Epstein Barr Virus Activated Innate Immunity In Vitro
Current Immunology Reviews (Discontinued) Mechanisms of Interferon Mediated Anti-Viral Resistance
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Benzimidazole Heterocycle as a Privileged Scaffold in Antiviral Agents
Mini-Reviews in Organic Chemistry Targeting the IL-6 Pathway in Multiple Myeloma and its Implications in Cancer-Associated Gene Hypermethylation
Medicinal Chemistry Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets A Comparative Study Among Various Statistical Tests Using Microarray Gene Expression Data
Current Bioinformatics Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
Current Medicinal Chemistry Concurrent Administration of Rituximab and CHOP Chemotherapeutic Agents for Outpatients with CD20-positive Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Preface
Current Pharmaceutical Design